4D Molecular Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 28, 2025
FDMT$12.48+1.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders
Statements of Stockholders’ Equity
(In thousands, except share amounts)
| Common Stock · AdditionalPaid-In · Accumulated Other Comprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Gain (Loss) | Deficit | Equity | |
| Balances at December 31, 2022 | 32,626,627 | $3 | $547,020 | $(1,196) | $(314,490) | $231,337 |
| Issuance of common stock upon exercise of stock options and warrants | 574,740 | — | 7,310 | — | — | 7,310 |
| Issuance of common stock for the ATM offering program | 1,098,612 | — | 19,348 | — | — | 19,348 |
| ATM offering costs | — | — | (680) | — | — | (680) |
| Issuance of common stock upon public offering, net of issuance costs | 8,625,000 | 1 | 129,207 | — | — | 129,208 |
| Stock-based compensation expense | — | — | 19,665 | — | — | 19,665 |
| Issuance of common stock - 2020 ESPP | 150,239 | — | 1,178 | — | — | 1,178 |
| Vesting of common stock warrants issued for services | — | — | 88 | — | — | 88 |
| Net unrealized gain on marketable securities | — | — | — | 1,212 | — | 1,212 |
| Net loss | — | — | — | — | (100,837) | (100,837) |
| Balances at December 31, 2023 | 43,075,218 | $4 | $723,136 | $16 | $(415,327) | $307,829 |
| Issuance of common stock upon exercise of stock options and vesting of RSUs | 427,036 | — | 4,580 | — | — | 4,580 |
| Issuance of common stock upon public offering, net of issuance costs - February / March 2024 Public Offering Sale | 7,845,314 | 1 | 316,148 | — | — | 316,149 |
| Issuance of common stock upon ATM offering, net of issuance costs | 585,938 | — | 15,263 | — | — | 15,263 |
| Issuance of common stock - 2020 ESPP | 170,436 | — | 1,258 | — | — | 1,258 |
| Issuance of pre-funded warrant for common stock conversions | (6,310,000) | — | — | — | — | — |
| Stock-based compensation expense | — | — | 26,116 | — | — | 26,116 |
| Vesting of common stock warrants issued for services | — | — | 66 | — | — | 66 |
| Net unrealized gain on marketable securities | — | — | — | 213 | — | 213 |
| Net loss | — | — | — | — | (160,868) | (160,868) |
| Balances at December 31, 2024 | 45,793,942 | $5 | $1,086,567 | $229 | $(576,195) | $510,606 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.